The narrowed loss and extended cash runway remove near-term financing overhang, but the stock will trade on pipeline catalysts. Watch for initial Phase 1 data from PRT12396 (JAK2V617F inhibitor) in 2H 2026 and the PRT13722 IND filing in mid-2026 — these are the key value inflection points. The Incyte option agreement provides a potential monetization path for the JAK2 program.
Price Chart
Executive Summary
Prelude Therapeutics reported Q1 2026 results with a net loss of $0.13 per share, significantly narrower than the $0.42 loss in Q1 2025, driven by a 67% reduction in R&D expenses after pausing SMARCA2 trials. The company generated $4.58M in revenue from its Incyte option agreement, initiated Phase 1 enrollment for lead asset PRT12396, and extended cash runway into Q2 2028 via a $90M underwritten offering. The combination of a narrower loss, first revenue, and extended runway is positive, but the company remains a pre-revenue clinical-stage biotech with no approved products.
Key Financial Metrics
Key Facts
- Q1 2026 net loss of $10.4M ($0.13/share) vs $32.1M ($0.42/share) in Q1 2025 — a 68% reduction
- Revenue of $4.58M from Incyte collaboration vs $0 in Q1 2025
- Cash, equivalents, restricted cash and marketable securities of $84.8M at March 31, 2026; subsequent $90M underwritten offering extends runway into Q2 2028
- Phase 1 enrollment initiated for PRT12396 (JAK2V617F mutant-selective inhibitor) in PV and MF patients
- IND filing for PRT13722 (KAT6A selective degrader) on track for mid-2026 with Phase 1 start in 2H 2026
- Appointed Charles Morris, M.D. as Chief Medical Officer in April 2026
- R&D expenses fell to $13.6M from $28.8M YoY due to paused SMARCA2 trials
- Weighted average shares outstanding increased to 82.5M from 76.0M YoY due to the April 2026 offering
Financial Impact
Net loss improved by $21.7M YoY; cash runway extended by ~1 year to Q2 2028 via $90M gross proceeds from underwritten offering
Risk Factors
- Clinical-stage biotech with no approved products — all pipeline assets are in early development
- Phase 1 data for PRT12396 may fail to replicate preclinical efficacy or safety
- Dilution from the $90M offering (shares outstanding grew ~8.6% from Dec 2025 to Mar 2026)
- Incyte option agreement may not be exercised, removing a key partnership revenue stream
- Cash runway assumes no unexpected clinical delays or cost overruns
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-218162 |
| Document: prld-20260512.htm | 0001193125-26-218162 |
| Document: prld-ex99_2.htm | 0001193125-26-218162 |
| Document: 0001193125-26-218162-index-headers.html | 0001193125-26-218162 |
| Document: 0001193125-26-218162-index.html | 0001193125-26-218162 |
| Document: 0001193125-26-218162.txt | 0001193125-26-218162 |
| 8-K Data (Synthetic) | 0001193125-26-218162 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 22, 2026 5w ago | Institutional Cluster | $4.85 $4.31 | ▼ −11.13% | ▼ −10.41% | $3.88 (−20.00%) |
Sep 10, 2026 6w ago | 8-K | $4.67 $4.59 | ▼ −1.71% | ▼ −2.57% | $3.88 (−16.92%) |
Sep 10, 2026 6w ago | Press Release | $4.67 $4.59 | ▼ −1.71% | ▼ −2.57% | $3.88 (−16.92%) |
Aug 11, 2026 11w ago | 8-K | $5.32 $5.73 | ▲ +7.71% | ▲ +7.46% | $3.88 (−27.07%) |
Aug 11, 2026 11w ago | Press Release | $5.32 $5.73 | ▲ +7.71% | ▲ +7.46% | $3.88 (−27.07%) |
May 12, 2026 24w ago | 8-K | $4.64 $4.66 | ▲ +0.43% | ▼ −0.14% | $3.88 (−16.38%) |
May 12, 2026 24w ago | Press Release | $4.64 $4.66 | ▲ +0.43% | ▼ −0.14% | $3.88 (−16.38%) |
Apr 28, 2026 26w ago | 3 | $4.27 $4.27 | · 0.00% | ▼ −1.02% | $3.88 (−9.13%) |
Apr 21, 2026 27w ago | Insider Cluster | $4.27 $5.23 | ▲ +22.48% | ▲ +21.46% | $3.88 (−9.13%) |
Apr 20, 2026 27w ago | 8-K | $4.51 $4.62 | ▲ +2.44% | ▲ +3.09% | $3.88 (−13.97%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers